Plasma noradrenaline and the prognosis of chronic cardiac failure: A multicenter study;Importance de la noradrenaline plasmatique pour l'evaluation pronostique de l'insuffisance cardiaque chronique: Etude multicentrique

Archives des Maladies du Coeur et des Vaisseaux

Volumn 91, Issue 2, 1998, Pages 191-199

  Geslin, P ^a   Le Bouil, A ^a   Furber, A ^a   Dupuis, J M ^a   Bouhour, J B ^b   Lanfranchi, J ^c   Monassier, J P ^d   Ferrieres M ^e   Tadei, A ^a   Allain, P ^a  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b Service De Cardiologie   (France)

^c AVICENNE HOSPITAL   (France)

^d Service de Cardiologie   (France)

^e HÔPITAL ARNAUD DE VILLENEUVE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NORADRENALIN; BIOLOGICAL MARKER;

ADULT; AGE; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE SEVERITY; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; NORADRENALIN BLOOD LEVEL; PREDICTION; SODIUM BLOOD LEVEL; SURVIVAL; BLOOD; CONGESTIVE HEART FAILURE; FEMALE; MALE; MIDDLE AGED; MULTICENTER STUDY; PROGNOSIS;

ADULT; AGED; BIOLOGICAL MARKERS; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; NOREPINEPHRINE; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 0031991753     PISSN: 00039683     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Cohn JN. Prognosis factors in heart failure : poverty amidst a wealth of variables. J Am Coll Cardiol 1989 ; 14 : 571-2.
2. Francis GS, Benedict C, Johnstone DE et al. Comparison of neuroendocrine activation in patients with left ventricular dysfonction with and without congestive heart failure : a substudy of the studies of left ventricular dysfunction (SOLVD). Circulation 1990 ; 82 : 1724-9.
3. Ferguson DW. Sympathetic mechanisms in heart failure. Pathophysiological and pharmacological implications. Circulation 1993 ; 87 : VII 68-VII 75.
4. Thomas J, Marks B. Plasma norepinephrine in congestive heart failure. Am J Cardiol 1978 ; 41 : 233-4.
5. Cohn JN, Levine T, Olivari M et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984 ; 311 : 819-23.
6. Packer M, Lee WH, Kessler PD et al. Role of neurohormonal mechanisms in determining survival in patients with severe chronic heart failure. Circulation 1987 ; 75 : (suppl IV) : 80-92.
7. Costanzo MR, Augustine S, Bourge R et al, Selection and treatment of candidates for heart transplantation. A statement for health professionals from the committee on heart failure and cardiac transplantation of the council on clinical cardiology, American Heart Association. Circulation 1995 ; 92 : 3595-612.
8. Di Carlo L, Chatterjee K, Parmley WW et al. Enalapril : A new angiotensin-converting enzyme inhibitor in chronic heart failure : acute and chronic hemoaynamic evaluations. J Am Coll Cardiol 1983 ; 2 : 865-71.
9. Levine TB, Cohn JN. Determinants of acute and long-term response to converting enzyme inhibitors in congestive heart failure. Am Heart J 1982 ; 104 : 1159-64.
10. Premel-Cabic A, Turcant A, Cailleux A, Allain P. Détermination de la noradrénaline plasmatique par Chromatographie liquide haute pression en mode automatique avec détection électrochimique. Path Biol 1984 ; 32 : 739-42.
11. Komajda M, Jais JP, Goldfarb B et al. Facteurs prédictifs de mortalité dans les myocardiopathies dilatées. Arch Mal Cœur 1990 ; 83 : 899-906.
12. Stevenson WG, Stevenson LW, Middlekauff HR et al. Improving survival for patients with advanced heart failure : a study of 737 consecutive patients. J Am Coll Cardiol 1995 ; 26 : 1417-23.
13. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L, for the CONSENSUS trial study group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990 ; 82 : 1730-6.
14. Rouleau JL, Packer M, Moye L et al. Prognostic value of neurohormonal activation in patients with an acute myocardial infarction : effect of Captopril. (SAVE). J Am Coll Cardiol 1994 ; 24 : 583-91.
15. Rector TS, Olivari MT, Levine TB, Francis GS, Cohn JN. Predicting survival for an individual with congestive heart failure using plasma norepinephrine. Am Heart J1987 ; 114 : 148-52.
16. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A, for the V-HeFT VA cooperative studies group. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. Circulation 1993 ; 87 (suppl VI) : VI 40-VI 48.
17. Benedict CR, Shelton B, Johnstone DE et al for the SOLVD investigators. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. Circulation 1996 ; 94 : 690-7.
18. Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation 1986 ; 73 : 257-67.
19. 220 % secondary to ischemic or non-ischemic dilated cardiomyopathy. Am J Cardiol 1990 ; 66 : 1348-54.
20. Curtiss C, Cohn JN, Vrobel T, Franciosa JA. Role of the reninangiotensin system in the systemic vasoconstriction of chronic congestive heart failure. Circulation 1978 ; 58 : 763-70.
21. Kluger J, Cody RJ, Laragh JH. The contributions of sympathetic tone and the renin-angiotensin system to severe chronic congestive heart failure : response to specific inhibitors (prazosin and captopril). Am J Cardiol 1982 ; 49 : 1667-74.
22. Kelly TS, Cremo R, Nielsen C, Shabetai R, Prediction of outcome in late-stage cardiomyopathy. Am Heart J 1990 ; 119 : 1111-21.
23. Wilson JR, Schwartz JS, Sutton M et al. Prognosis in severe heart failure : relation to hemodynamic measurements and ventricular ectopic activity. J Am Coll Cardiol 1983 ; 2 : 403-10.
24. Stevenson LW, Coper G, Natterson B et al. Target heart failure populations for newer therapies. Circulation 1995 ; 92 (suppl II): II 174-II 181.
25. Cohn JN, Jonhson GR, Shabetai R et al for the V-HeFT VA cooperative studies group. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias and plasma norepinephrine as determinants of prognosis in heart failure. Circulation 1993 ; 87 (suppl VI) : VI 5-VI 16.
26. Dec GW, Fifer MA, Herrmann HC, Cocca-Spofford D, Semigram MJ. Long-term outcome of enoximone therapy in patients with refractory heart failure. Am Heart J 1993 ; 125 : 423-9.
27. Stevenson LW. Selection and management of candidates for heart transplantation. Curr Opin Cardiol 1996 ; 11 : 166-73.
28. Cintron GB, Johnson G, Francis GS, Cohs J, VA cooperative group. Prognostic significance of serial changes in left ventricular ejection Traction in heart failure : V-HeFT I and II. Circulation 1992 ; 86 : 251.
29. Kao W, Gheorgiode M, Hall V, Goldstein S. Relation between plasma norepinephrine and response to medical therapy in men with congestive heart failure secondary to coronary artery disease or idtopathic dilated cardiomyopathy. Am J Cardiol 1989 ; 64 : 609-13.